NLS Pharmaceutics received another delisting warning from Nasdaq on May 22, 2024, due to insufficient stockholders' equity.

NLS Pharmaceutics, a Swiss clinical-stage biopharmaceutical firm, has announced it received an additional staff delisting determination letter from Nasdaq on May 22, 2024. The company did not meet the minimum $2.5m stockholders' equity requirement, which could lead to its securities being delisted from Nasdaq. This further delisting issue comes after an initial notification on April 19, 2024.